272 related articles for article (PubMed ID: 23120745)
1. Integrins and p53 pathways in glioblastoma resistance to temozolomide.
Martin S; Janouskova H; Dontenwill M
Front Oncol; 2012; 2():157. PubMed ID: 23120745
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy based on p53 reactivation reduces both glioblastoma cell growth and resistance to temozolomide.
Forte IM; Indovina P; Iannuzzi CA; Cirillo D; Di Marzo D; Barone D; Capone F; Pentimalli F; Giordano A
Int J Oncol; 2019 Jun; 54(6):2189-2199. PubMed ID: 31081046
[TBL] [Abstract][Full Text] [Related]
3. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide-Acquired Resistance Is Associated with Modulation of the Integrin Repertoire in Glioblastoma, Impact of α5β1 Integrin.
Sani S; Pallaoro N; Messe M; Bernhard C; Etienne-Selloum N; Kessler H; Marinelli L; Entz-Werle N; Foppolo S; Martin S; Reita D; Dontenwill M
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053532
[TBL] [Abstract][Full Text] [Related]
6. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience.
Bock HC; Puchner MJ; Lohmann F; Schütze M; Koll S; Ketter R; Buchalla R; Rainov N; Kantelhardt SR; Rohde V; Giese A
Neurosurg Rev; 2010 Oct; 33(4):441-9. PubMed ID: 20706757
[TBL] [Abstract][Full Text] [Related]
7. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
8. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
10. Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
Janouskova H; Maglott A; Leger DY; Bossert C; Noulet F; Guerin E; Guenot D; Pinel S; Chastagner P; Plenat F; Entz-Werle N; Lehmann-Che J; Godet J; Martin S; Teisinger J; Dontenwill M
Cancer Res; 2012 Jul; 72(14):3463-70. PubMed ID: 22593187
[TBL] [Abstract][Full Text] [Related]
11. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
12. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results.
Scaringi C; Minniti G; Caporello P; Enrici RM
Anticancer Res; 2012 Oct; 32(10):4213-23. PubMed ID: 23060541
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients.
Pan E; Mitchell SB; Tsai JS
J Neurooncol; 2008 Jul; 88(3):353-7. PubMed ID: 18389176
[TBL] [Abstract][Full Text] [Related]
14. The role of integrins in glioma biology and anti-glioma therapies.
Tabatabai G; Tonn JC; Stupp R; Weller M
Curr Pharm Des; 2011; 17(23):2402-10. PubMed ID: 21827415
[TBL] [Abstract][Full Text] [Related]
15. FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling.
Lu C; Cui C; Liu B; Zou S; Song H; Tian H; Zhao J; Li Y
Neurosci Lett; 2017 Sep; 657():77-83. PubMed ID: 28778805
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM.
Stojcheva N; Schechtmann G; Sass S; Roth P; Florea AM; Stefanski A; Stühler K; Wolter M; Müller NS; Theis FJ; Weller M; Reifenberger G; Happold C
Oncotarget; 2016 Mar; 7(11):12937-50. PubMed ID: 26887050
[TBL] [Abstract][Full Text] [Related]
17. Protein alterations associated with temozolomide resistance in subclones of human glioblastoma cell lines.
Sun S; Wong TS; Zhang XQ; Pu JK; Lee NP; Day PJ; Ng GK; Lui WM; Leung GK
J Neurooncol; 2012 Mar; 107(1):89-100. PubMed ID: 21979894
[TBL] [Abstract][Full Text] [Related]
18. Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma.
Li Q; Chen B; Cai J; Sun Y; Wang G; Li Y; Li R; Feng Y; Han B; Li J; Tian Y; Yi L; Jiang C
PLoS One; 2016; 11(3):e0151815. PubMed ID: 27022952
[TBL] [Abstract][Full Text] [Related]
19. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
20. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
